Evidence map›Paper›PMID 33407005›Full record

ArticleEmerging microbes & infections2021

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission.

Young-Il Kim, Se-Mi Kim, Su-Jin Park, Eun-Ha Kim, Kwang-Min Yu, Jae-Hyung Chang, Eun Ji Kim, Mark Anthony B Casel, Rare Rollon, Seung-Gyu Jang and 14 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Ferrets: A powerful model of SARS-CoV-2.Zoological research · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection.Mayo Clinic proceedings. Innovations, quality & outcomes · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 2 countries.

Young-Il KimCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0002-0145-7382
Se-Mi KimCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0001-7932-1381
Su-Jin ParkCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0002-8915-4799
Eun-Ha KimCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0003-1443-3416
Kwang-Min YuCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0001-6692-6525
Jae-Hyung ChangCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.
Eun Ji KimCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0001-5203-2125
Mark Anthony B CaselCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0002-8313-4076
Rare RollonCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0002-8428-1713
Seung-Gyu JangCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0001-9316-1652
Jihye UmResearch institute of Public Health, National Medical Center, Seoul, Republic of Korea.
Min-Suk SongCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0001-6073-0783
Hye Won JeongCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0002-1063-8476
Eung-Gook KimCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0001-8232-5666
Yeonjae KimResearch institute of Public Health, National Medical Center, Seoul, Republic of Korea.
So Yeon KimResearch institute of Public Health, National Medical Center, Seoul, Republic of Korea.
Jun-Sun ParkResearch institute of Public Health, National Medical Center, Seoul, Republic of Korea.
Mi Sun ParkDiv. of Public Health Research, Sejong Institute of Health & Environment, Sejong City, Republic of Korea.
Geun-Yong KwonSejong Public Health Center, Sejong City, Republic of Korea.
Sang Gu YeoDiv. of Public Health Research, Sejong Institute of Health & Environment, Sejong City, Republic of Korea.
Shin-Ae LeeDepartment of Cancer Biology and Center for Global and Emerging Pathogen Research, Lerner Research Institute, Cleveland, OH, USA.
Youn Jung ChoiDepartment of Cancer Biology and Center for Global and Emerging Pathogen Research, Lerner Research Institute, Cleveland, OH, USA.
Jae U JungDepartment of Cancer Biology and Center for Global and Emerging Pathogen Research, Lerner Research Institute, Cleveland, OH, USA.ORCID https://orcid.org/0000-0003-4559-8774
Young Ki ChoiCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.ORCID https://orcid.org/0000-0002-0872-0147
Chungbuk National University · KRSejong Institute · KRCerner (United States) · USNational Medical Center · KR

Funding

Molecular Basis of KSHV oncogenesisR35CA200422 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2016 to 2022
$6.1M
SFTSV nonstructural protein NSs-mediated immunopathogenesisR01AI140705 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2018 to 2022
$4.2M
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKVR01AI140718 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG, JUNG, JAE U · 2018 to 2022
$3.8M
Tickborne SFTS Virus Vaccine DevelopmentR01AI152190 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI JUNG, JAE U · 2020 to 2024
$2.9M
TRIM9-mediated anti-viral immune pathwayR01AI116585 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI OU, J.-H. JAMES · 2015 to 2019
$2.3M
NCI NIH HHS R35 CA200422NIAID NIH HHS R01 AI116585NIAID NIH HHS R01 AI140705NIAID NIH HHS R01 AI140718NIAID NIH HHS R01 AI152190
6 · The paper itself

Abstract

Cases of laboratory-confirmed SARS-CoV-2 reinfection have been reported in a number of countries. Further, the level of natural immunity induced by SARS-CoV-2 infection is not fully clear, nor is it clear if a primary infection is protective against reinfection. To investigate the potential association between serum antibody titres and reinfection of SARS-CoV-2, ferrets with different levels of NAb titres after primary SARS-CoV-2 infection were subjected to reinfection with a heterologous SARS-CoV-2 strain. All heterologous SARS-CoV-2 reinfected ferrets showed active virus replication in the upper respiratory and gastro-intestinal tracts. However, the high NAb titre group showed attenuated viral replication and rapid viral clearance. In addition, direct-contact transmission was observed only from reinfected ferrets with low NAb titres (<20), and not from other groups. Further, lung histopathology demonstrated the presence of limited inflammatory regions in the high NAb titre groups compared with control and low NAb groups. This study demonstrates a close correlation between a low NAb titre and SARS-CoV-2 reinfection in a recovered ferret reinfection model.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralChlorocebus aethiopsCOVID-19FerretsReinfectionSARS-CoV-2Vero CellsAntibodies, NeutralizingAntibodies, ViralCOVID-19ferret modelneutralizing antibodyreinfectionSARS-CoV-2

Identifiers

PMID33407005
PMCPMC7832474
OpenAlexW3119953480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.